期刊文献+

125例贝伐珠单抗注射液的不良反应报告分析 被引量:3

原文传递
导出
摘要 目的:探讨贝伐珠单抗注射液不良反应发生的特点及相关因素,为临床安全用药提供参考。方法:收集某省药物不良反应监测中心2004-2011年自发呈报系统上报的125例贝伐珠单抗注射液的不良反应(ADR)报告,对药物ADR所涉及的患者年龄、性别、原患疾病,ADR的类型、结果、临床表现等进行统计分析。结果:125例报告中,男64例,女61例,50岁以上患者最多(63.20%);发生严重ADR36例,新的严重ADR 27例;临床表现以胃肠系统损害为主,占33.60%,其次为血液系统损害,占15.10%。结论:临床应重视贝伐珠单抗注射液的ADR,以促进临床合理用药,减少和避免ADR的发生。
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2013年第9期749-751,共3页 Chinese Journal of Hospital Pharmacy
  • 相关文献

参考文献3

  • 1程刚,张力.贝伐珠单抗治疗非小细胞肺癌的相关不良反应及处理原则[J].中国肺癌杂志,2010,13(6):563-567. 被引量:36
  • 2Sandier A, Gray R, Perry MC, et al. Paclitaxel-carboplatin a- lone or with bevaeizumab for non-small lung cancer[J]. N Eng J Med, 2006, 355(24) : 2542-2550.
  • 3Dansin E, Tsai CM, Pavlakis N, et al. Safety and efficacy of first-line heva cizumab-based therapy in advanced non-small cell lung cancer (NSCLC) ; results of the SaiL study (MO19390) [J]. Eur J Cancer Suppl, 2009, 7(2) :556.

二级参考文献24

  • 1Folkman J. Tumor angiogenesis: therapeutic implications. N Eng J Med, 1971, 285(21): 1182-1186.
  • 2Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med, 2003, 9(6): 669-676.
  • 3Avastin (bevacizumab) package insert. South San Francisco, CA: Genentech Inc; July 2009.
  • 4Sandier A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-ceU lung cancer. N Eng J Med, 2006, 355(24): 2542-2550.
  • 5Reck M, Pawel JV, Zatloukal P, et al. Phase Ⅲ trial ofcisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAIL. J Clin Oncol, 2009, 27(8): 1227-1234.
  • 6Dansin E, Tsai CM, Pavlakis N, et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-small cell lung cancer (NSCLC): results of the SaiL study (MO19390). Eur J Cancer Suppl, 2009, 7(2): 556.
  • 7Wu YL, Zhou CC, Jiang GL, et al. First-line bevacizumab plus chemotherapy in Chinese pateints with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): results of the SaiL trial (MO19390). APCC 2009 [ abstr: P95].
  • 8Zhu XL, Wu SH, Dahut WL, et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis, 2007, 49(2): 186-193.
  • 9Dimmeler S, Fleming I, Fisslthaler B, et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphrylation. Nature, 1999, 399(6736): 601-605.
  • 10He H, Venema VJ, Gu XL, et al. Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through Flk-1/ KDR activation of c-Src.J Bio Chem, 1999, 274(35): 25130-25135.

共引文献35

同被引文献25

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部